A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians

Journal of the National Medical Association

Volumn 103, Issue 6, 2011, Pages 518-523

  Lao, Cheng Kin ^a   Gruta, Cristina ^b   John, Malcolm D V ^b,c   Cocohoba, Jennifer ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Positive Care Center   (United States)

^d NONE

Author keywords

African Americans; Drugs; HIV AIDS; Kidney

Indexed keywords

CREATININE; RITONAVIR; TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG MONITORING; ETHNOLOGY; HUMAN IMMUNODEFICIENCY VIRUS; KIDNEY; KIDNEY FAILURE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT WITHDRAWAL; UNITED STATES;

ADENINE; ADULT; AFRICAN AMERICANS; ANTI-HIV AGENTS; CREATININE; DRUG MONITORING; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLOMERULAR FILTRATION RATE; HIV; HIV INFECTIONS; HUMANS; KIDNEY; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RENAL INSUFFICIENCY; UNITED STATES; WITHHOLDING TREATMENT;

EID: 80052348405     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0027-9684(15)30367-9     Document Type: Article

References (30)

1. Viread [package insert]. Foster City, CA: Gilead Sciences; 2008.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services; 2009. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed January 8, 2010.
3. Cirino CM, Kan VL. Hypokalemia in HIV patients on tenofovir. AIDS. 2006;20(12):1671-1673. (Pubitemid 44162412)
4. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35(3):269-273. (Pubitemid 38280652)
5. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J Infect. 2005;51(2):E61-E65. (Pubitemid 40984370)
6. Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med. 2004;117(4):282-284. (Pubitemid 39092726)
7. Mathew G, Knaus SJ. Acquired Fanconi's syndrome associated with tenofovir therapy. J Gen Intern Med. 2006;21(11):C3-C5. (Pubitemid 44506861)
8. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, et al. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS. 2004;18(6):960-963.
9. Hynes P, Urbina A, McMeeking A, et al. Acute renal failure after initiation of tenofovir disoproxil fumarate. Ren Fail. 2007;29(8):1063-1066. (Pubitemid 350232888)
10. Antoniou T, Raboud JM, Chirhin S, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med. 2005;6(4):284-290. (Pubitemid 41025294)
11. Winston A, Amin J, Mallon PWG, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med. 2006;7(2):105-111.
12. Gallant JE, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40(8):1194-1198. (Pubitemid 40490248)
13. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197(1):102-108. (Pubitemid 351263473)
14. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21(10):1273-1281. (Pubitemid 46883481)
15. Madeddu G, Bonfanti P, De Socio GV, et al. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother. 2008;62(1):6-11.
16. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520-529.
17. Fernando SK, Finkelstein FO, Moore BA, et al. Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci. 2008;335(2):89-94. (Pubitemid 351253402)
18. Wyatt CM, Morgello S, Katz-Malamed R, et al. The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int. 2009;75(4):428-434.
19. US Renal Data System. USRDS 2009 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009. www.usrds.org/adr-2009.htm. Accessed October 1, 2009.
20. Lucas GM, Lau B, Atta MG, et al. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis. 2008;197(11):1548-1557. (Pubitemid 351706485)
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
22. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470. (Pubitemid 29135798)
23. Division of AIDS Regulatory Support Center. Table for grading severity of adult and pediatric adverse events. http://rsc.tech-res.com/Document/ safetyandpharmacovigilance/Table-for-Grading-Severity-of-Adult-Pediatric- Adverse-Events.pdf. Accessed November 1, 2008.
24. Fux CA, Christen A, Zgraggen S, et al. Effect of tenofovir on renal glomerular and tubular function. AIDS. 2007;21(11):1483-1485. (Pubitemid 46988011)
25. Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 2009;23(15):1971-1975.
26. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48(11):108-116.
27. Halbesma N, Kuiken DS, Brantsma A, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17(9):2582-2590. (Pubitemid 44300975)
28. Hallan SI, Ritz E, Lydersen S, et al. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol. 2009;20(5):1069- 1077.
29. Labarga P, Barreiro P, Matin-Carbonero L, et al. Kidnegy tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009:23(6):689-696
30. Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, et al. Primary care guidelines for the management of persons infected with human immunodefiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:651-681.